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Abbreviation 
BCR: B-cell receptor 
CD: Cluster of differentiation 
CD40L: CD40 ligand 
ERK1/2: Extracellular Signal-Regulated Kinases 1 and 2 
MEK: Mitogen-Activated Protein Kinase Kinase  
PMA: Phorbol-12-Myristate-13-Acetate 
TCR: T-cell receptor 
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Abstract 
Background: An increased percentage of peripheral transitional B-cells producing 
IL-10 has been observed in patients tolerant to kidney allografts. In healthy 
volunteers, the balance between the CD40 and B-cell receptor (BCR) signalling 
modulated IL-10 production by B-cells, with stimulation via the BCR decreasing 
CD40-mediated-IL-10 production. In this study, we evaluate whether in tolerant 
kidney transplant patients the increased IL-10 production by B-cells was due to an 
altered CD40 and/or BCR signalling. 
Methods: B-cells obtained from a new cohort of tolerant renal transplant recipients 
and those from age- and gender-matched healthy volunteers, were activated via 
CD40 and BCR, either alone or in combination. 
Results: In tolerant patients we observed higher percentages of B-cells producing 
IL-10 after CD40 ligation and higher expression of CD40L on activated T-cells, 
compared to healthy controls. Furthermore, B-cells from tolerant recipients had 
reduced ERK signalling following BCR-mediated activation compared to healthy 
controls. In keeping with this, combining BCR signalling with CD40 ligation did not 
reduce IL-10 secretion as was observed in healthy control transitional B-cells.  
Conclusion: Altogether our data suggests that the altered response of B-cells in 
tolerant recipients may contribute to long-term stable graft acceptance. 
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Introduction 
A state of operational tolerance has been described in kidney transplant patients 
who deliberately decided to stop immunosuppression1. These patients displayed a 
stable graft function after complete drug withdrawal for longer than one year. In 
2007, Brouard et al. performed the first study in kidney transplant patients aimed at 
identifying biomarkers of tolerance from peripheral blood samples, defining a 
“tolerant fingerprint” of 49 genes2. The same group reported later that tolerant 
recipients exhibited a significant increase in absolute numbers and frequency of total 
B-cells, particularly activated memory and early memory B-cells3. In the same year, 
two independent multicentre studies, the European IOT study4 and the USA ITN 
study5 reported and validated a B-cell signature in 11 and 19 kidney transplant 
tolerant patients, respectively. In both studies an over-expression of multiple B-cell 
related genes and maintenance of peripheral blood B-cell numbers and percentages 
in tolerant recipients were observed. Moreover, in the ITN study an up-regulation of 
CD20 mRNA in sediment cells from urine, and elevated numbers of peripheral blood 
naïve and transitional B-cells in tolerant participants, compared with those receiving 
immunosuppression, were also observed5. In 2012, another group reported that 
tolerant recipients exhibited similar numbers and percentages of circulating total B-
cells, naive, memory and regulatory B-cells than healthy individuals, as well as 
preserved B-cell receptor repertoire. In addition, they demonstrated that tolerant 
recipients displayed a conserved capacity to activate CD40/STAT3 signalling 
pathway in regulatory B-cells6. In 2014, Brouard’s group showed that B-cells from 
tolerant recipients exhibited a defective expression of factors involved in the 
differentiation into plasma cells and the B-cells were more prone to cell death by 
apoptosis compared to patients with stable graft function7. Finally in 2015, the same 
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group showed that tolerant recipient exhibit a higher number of Granzyme B+ B-cells 
compared to healthy volunteers and stable recipients 8. They showed that Granzyme 
B+ B-cells were able to inhibit CD25-CD4+Tcell responses through a pro-apoptotic 
mechanism8. 
CD40 and BCR ligation on B-cells are key events in their function and T-cells 
contribute to both. The predominance of the BCR signalling alone favoures 
apoptosis9,  whereas the predominance in the CD40 ligation favoures cell survival9 
and IL-10 secretion10. The combination of both signals favoures cell activation, 
differentiation and antibody production11, however it has been reported that IL-10 
production by CD27-B-cells is reduced when CD40 and BCR are triggered together 
compared to CD27-B-cells activated only through CD40-CD40L interaction10.1  
In this study we hypothesised that altered BCR/CD40 signalling is linked to 
increased IL-10 production observed in tolerant patients. The B-cell responses from 
a cohort of tolerant renal transplant recipients were compared with age/gender-
matched healthy volunteers. The data presented in our study demonstrated that B-
cells from tolerant patients exhibited an imbalance in CD40/BCR signalling 
compared to healthy controls, suggesting that these differences may contribute their 
increased IL-10 production and to the long-term graft survival observed in tolerant 
patients. 
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Materials and Methods 
Patients 
Patient samples were donated from the Genetic Analysis & Monitoring of Biomarker 
of Immunological Tolerance (GAMBIT) study, approved by the Institute of Child 
Health/Great Ormond Street Hospital Research Ethics Committee 09/H0713/12. All 
experiments were performed in accordance with the approved guidelines and 
regulations. Samples were processed and analysed in a blinded fashion after 
informed consent was obtained from all subjects. Of patients from the GAMBIT 
study, the following ones have been used in this project:  
Tolerant (n=16): Functionally stable kidney transplant recipients despite having 
stopped all their immunosuppression for longer than one year with a serum 
creatinine CRT < 160umol/l and < 10% rise in the last 12 months. ESRF causes 
have been summarised in SupplTable 1. Healthy control (n=11): Healthy volunteers 
were age and gender-matched to tolerant patients.  
Patient characteristics are described in Table 1. 
Sample Collection 
PBMCs from patients and healthy controls were isolated from peripheral blood by 
Ficoll-Hypaque (PAA) density gradient centrifugation. Cells were re-suspended in 
10% DMSO (Sigma-Aldrich)-AB human serum (BioWest) and frozen immediately at -
80°C. After 24hrs, cells were transferred into liquid nitrogen where they were kept 
until use. Cell counts for each patient were obtained from their respective full blood 
count test (FBC; NHS). Serum samples were obtained after centrifugation of 
coagulated peripheral blood samples (2000RPM/20min/room temperature), stored at 
-80°C and kept until use. 
B-cell phenotypic studies 
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PBMC samples were thawed from liquid nitrogen on the same day as the staining 
and 3x106 PBMCs were used to study B-cell phenotype. PBMCs were stained with 
Live/Dead (Invitrogen), anti-IgM-PercP-Cy5.5 (BD), anti-IgD-PE (BD), anti-CD19-
AlexaFluor780, anti-CD20-AlexaFluor700, anti-CD27-APC, anti-CD24-FITC, anti-
CD38-PECy7 (all eBioscience) for 30min at 4°C. Cells were acquired on 
LSRFortessa (BD). Data was acquired until at least 5,000 events in the B-cell subset 
were counted. All flow cytometry data was analysed using FlowJo (Tree Star, Inc. 
Ashland, OR 97520 USA) or DIVA software (BD).   
B-cell functional assays in response to CD40L activation measured in kidney 
transplant patient and healthy control’s PBMCs   
1x106 PBMCs from patient samples were cultured with or without 0.5x105 plate 
bound CD40L-transfected and non-transfected mouse L-fibroblast cells (X-ray 
irradiated for 30min 9,045 cGy) for 72hrs. After 3 days, expression of CD86-FITC 
and CD25-PE (all eBioscience) and intracellular IL-10-PE (BD) and TNF- 
(eBioscience) were measured in CD20+B-cells. Supernatants were collected and 
stored at -80°C to subsequently measure cytokines by ELISA. Methods for 
intracellular staining, ELISA and experiments in B-cell subsets isolated from healthy 
leukocytes retained in filtering cones and patient samples can be found in the 
supplementary content. 
T-cell activation 
CD4+T-cells were isolated using CD4+T-cell Isolation Kit II, human (Miltenyi Biotec). 
Cells were activated with CD3/CD28 beads (1:2 ratio) (Invitrogen) for 8 and 48hrs. 
After 8hrs, cells were stained with CD4-FITC (eBioscience) and CD40L-PE 
(eBioscience) for 30min at 4°C. Cytokines in the supernatants were measured using 
Cytometric Beads Array human Th1/Th2/Th17 kit (BD) For IL-2: the sensitivity of the 
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kit was 2.6 pg/mL and the standard curve range was from 2.6 to 5000 pg/mL. For IL-
4: the sensitivity of the kit was 4.9 pg/mL and the standard curve range was from 4.9 
to 5000 pg/mL. Cells and beads were acquired on LSRFortessa (BD).  
BCR activation measured on patient’s PBMCs 
PBMCs from patients and healthy controls were thawed and rested overnight in 
media supplemented with IL-2 (100ng/ml, R&D) at 37°C 5% CO2. The next day, cells 
were stained with CD20-Pacific Blue (eBioscience), CD27-APC (eBioscience), 
CD24-PE (eBioscience), CD38-PE-Cy7 (eBioscience) and Live/Dead dye 
(Invitrogen) for 20min at 37○C 5% CO2. After the staining, 1x106 PBMCs were placed 
in FACS tubes, cells were washed, rested for 30min at 37○C 5% CO2 and activated 
with anti-IgM (20g/ml)/anti-IgG (20g/ml) (Southern Biotech) for 0, 10 and 30min 
and with PMA (0.1M, SIGMA) for 10min at 37°C. Cells were fixed with BD Cytofix 
buffer (BD) for 10min at 37°C, permeabilized with BD Phosflow Perm Buffer III (BD) 
for 30min on ice and stained with anti-ERK1/2 (pT202/pY204)-AlexaFluor488 (BD) 
for 30min at 4°C. Cells were acquired on LSRFortessa (BD).  
Detection of IgG1 serum levels 
Serum IgG1 levels were measured with the Human Immunoglobulin Isotyping 
Magnetic Bead Panel Milliplex Map Kit (Millipore) in healthy volunteers and tolerant 
recipients. 
Statistical analysis 
All columns in graphs represent the mean and standard error of mean. Non-
parametric Mann-Whitney test was used to analyse phenotypic flow cytometry data 
in patient and healthy control samples. Two-way Repeated Measurement (RM) 
ANOVA test with Sidak’s multiple comparisons was used to evaluate differences 
between non-activated and activated samples. We defined significance as **** 
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P<0.0001, *** P<0.001, ** P<0.01 and * P<0.05. We performed data tables, 
statistical analysis results and graphs using Prism 6 (1992-2012 GraphPad Software, 
Inc La Jolla, CA 92037 USA).  
 12 
Results 
Tolerant kidney transplant recipients exhibit higher percentages of IL10+ B-
cells after CD40L activation compared to healthy volunteers  
Previous studies, from us and others, have established that the percentages of total 
B-cells in tolerant renal transplant patients were similar to healthy volunteers3,5,6. 
This was confirmed in a new cohort of tolerant recipients (Table.1) in whom similar 
percentages of total, memory, naïve and transitional B-cells between healthy 
controls and tolerant recipients were observed (Fig.1A and Fig.S1).  
IL-10 production has been shown to be the main regulatory mechanism for 
transitional B-cells in autoimmunity12, GVHD13, as well as transplantation5,7,14, 
therefore, the production of this cytokine was studied in the new cohort of tolerant 
patients. B-cells were stimulated via CD40 molecules by using CD40L-expressing L-
cells, and as control non-transfected L-cells. CD40 stimulation of B-cells, in healthy 
volunteers sorted B-cell subsets isolated from peripheral blood cones, preferentially 
induced IL-10 production by transitional B-cells, while the TLR9 agonist CpG, used 
as positive control, led to IL-10 production by all the different B-cell subsets (Fig.S2). 
After confirming that CD40-ligation was inducing IL-10 mainly in transitional B-cells, 
the production of IL-10 was then compared in B-cells between healthy volunteers 
and tolerant patients. The percentage of IL-10+B-cells and the levels of IL-10 in the 
supernatants were significantly higher in samples from tolerant recipients compared 
to healthy volunteers, while no differences in the levels of TNF- between the two 
groups was observed (Fig.1B). To confirm that the difference in IL-10 production 
between tolerant patients and healthy individuals was not due to differences in the 
susceptibility of B-cells to be activated, the expression of CD25 and CD86 molecules 
by B-cells after CD40-ligation was analysed. Similar up-regulation of both molecules 
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was observed in the two cohorts of individuals (Fig.1C).  
T-cells are key in the activation of B-cells and the engagement of CD40 expressed 
by B-cells by CD40L on T-cells is essential in inducing IL-10 production12. Therefore, 
we measured the expression of CD40L on CD4+T-cells from tolerant patients and 
healthy controls. We observed that the levels of expression of CD40L, while similar 
between the two cohorts of individuals before T-cell activation, were higher 8hrs-post 
activation with CD3/CD28 beads, in T-cells from tolerant patients, suggesting that T-
cells from tolerant recipients have an advantage in engaging CD40 molecules on B-
cells compared to healthy volunteers (Fig.1D).  
 
B-cells from tolerant recipients have decreased BCR signalling compared to 
healthy volunteers. 
We have shown so far that tolerant patients exhibited increased IL-10 production by 
B-cells and that CD40L expression is higher in T-cells compared to healthy 
volunteers. Another function of B-cells that may be relevant for the maintenance of a 
tolerant state, is their capacity to bind antigen via the BCR and then present it to T-
cells15. At the same time, it has been shown previously that BCR engagement leads 
to the maturation and activation of B-cells via the MEK-ERK signalling pathway16. 
Therefore, the phosphorylation of ERK was evaluated by stimulating B-cells with 
anti-IgG/anti-IgM (Fig.2A and B). Activation with PMA, that bypasses the BCR, was 
used as a positive control (Fig.2B). The results are presented as the differences in 
phosphorylation between samples activated via the BCR for 10min and non-
activated (ΔERK) (Fig.2C). All B-cell subsets from tolerant recipients exhibited 
reduced ΔERK compared to healthy controls (Fig.2D), while no differences in ΔERK 
were observed after PMA activation (Fig.2E), suggesting that the reduction in ERK 
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phosphorylation in the B-cells from tolerant recipients was specific to the BCR 
stimulation. CD40-mediated IL-10 production by CD27-B-cells was inhibited with 
simultaneous CD40 and BCR stimulation10. As predicted, IL-10 production was 
reduced in transitional B-cells from healthy individuals when B-cells were stimulated 
via CD40 and BCR compared to ligation of CD40 alone (Fig.2F and Fig.S3). In 
addition, we observed that the combination of CD40 and BCR stimulation resulted in 
down-regulation of ERK-phosphorylation compared to BCR stimulation alone 
(Fig.S4). Having shown that the effect on IL-10 release was mainly observed in the 
transitional population, IL-10 production by transitional B-cells in response to ligation 
of CD40 and BCR was compared between healthy individuals and tolerant patients. 
We found that, whereas IL-10 production following CD40 and BCR stimulation was 
decreased in transitional B-cells from healthy volunteers, it was maintained in 
transitional B-cells from tolerant recipients (Fig.2G). These results suggest that the 
reduced BCR signalling present in B-cells from tolerant recipients allowed sustained 
CD40-mediated IL-10 production after dual activation.  
It has been described that mice deficient for Ras guanyl nucleotide exchange factor 
3 (Rasgrp3−/−), exhibit reduced ERK phosphorylation after BCR activation and lower 
titters of IgG1 in their sera17, suggesting that reduction in the BCR-ERK signalling 
plays a role in the humoral response, skewing it to IgG subclasses with lower 
complement binding. Furthermore, IL-2 and IL-4 present during the class-switch also 
affect the production of IgG118,19. Therefore, the production of these two cytokines by 
CD4+T-cells from patients and healthy volunteers was measured after TCR 
activation. The analysis of these cytokines after 48hrs of culture revealed that the 
levels of IL-2 and IL-4 were lower in T-cells from tolerant patients compared to 
healthy controls (Fig.2H). In accordance with reduced BCR signalling and reduced 
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levels of IL-2 and IL-4, lower levels of IgG1 were found in the serum of tolerant 
recipients compared to healthy volunteers (Fig.2I). 
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Discussion 
Here we describe for the first time that tolerant patients exhibit higher percentages of 
IL-10-producing B-cells after CD40 activation and reduced BCR signalling compared 
to healthy controls. We also demonstrated that the reduction in BCR signalling 
favoured IL-10 production in the transitional B-cell population of tolerant recipients. 
Furthermore, the reduced ERK activation together with the reduced IL-2 and IL-4 
production by T-cells may contribute to the low IgG1 levels observed in the serum 
(Fig.S5). 
The percentages of B-cells and the expression of B-cell related genes has been 
previously compared between tolerant patients and either healthy individuals or other 
groups of patients under immunosuppressive therapy3-6. Newell et al. reported for 
the first time that following stimulation with PMA+Ionomycin, transitional B-cells from 
tolerant individuals expressed higher percentages of IL-10 relative to stable patients 
or healthy controls5. Although their differences were significant, they recognised that 
the overall percentages of IL-10 producing B-cells were extremely low, with many 
samples containing no IL-10-producing cells, and with a large overlap in IL-10 
expression between groups, suggesting that PMA+Ionomycin may not have been 
the optimal stimulus to measure IL-10-producing B-cells within PBMCs. On the other 
hand, data from Silva et al. using specific CD40 activation, showed higher STAT-3 
phosphorylation in regulatory B-cells from 5 tolerant patients compared to patients 
with chronic rejection, indicating that the IL-10 signalling pathway was activated in 
tolerant recipients6. More recently, Chesneau et al., demonstrated higher IL-10 
production by B-cells from tolerant kidney transplant patients compared to healthy 
volunteers and stable recipient after a combination of anti-IgG/IgM/IgA, soluble 
CD40L, CpG and IL-27. However, the addition of CpG in the latter study complicated 
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the interpretation of the results, as CpG induced IL-10 production by a different 
signalling pathway compared to CD40 and by different B-cell subsets (Fig.S2). Here 
we showed that CD40L activation induces IL-10 production preferentially by 
transitional B-cells and that IL-10 production was higher in transitional B-cells from 
tolerant patients after dual-BCR/CD40L activation compared to healthy volunteers. 
Since these activations targeted mainly the transitional B-cell population, it is difficult 
to compare the IL-10 production between tolerant recipients and patients under 
immunosuppressive treatment as the latter patients exhibited extremely low 
percentages of transitional B-cells (data not shown). 
IL-10 is a well-known anti-inflammatory cytokine. The production of IL-10 by B-cells 
has been shown to inhibit T-cell proliferation13, cytokine production12 and promote 
regulatory T-cell differentiation20. Furthermore, IL-10 also attenuates the antigen 
presentation capacity of B-cells by down-regulating the expression of CD86 on their 
surface in mouse21 and human14. In human diseases, IL-10 production has been 
proposed as the main regulatory mechanism used by B-cells in lupus12, arthritis20. 
graft-versus-host disease (GVHD)13 and transplantation22. The production of IL-10 in 
tolerant recipients may indicate that in these patients it may contribute to the 
maintenance of a stable graft function in the absence of any immunosuppressive 
therapy. 
Along with more IL-10 production, B-cells from tolerant recipients also exhibited a 
reduced BCR signalling. Mice with impaired BCR signalling exhibited lower titters of 
IgG1 in the sera compared to wild-type mice17 suggesting that reduced BCR 
signalling affects the Ig class-switch to IgG1. Furthermore, Chesneau et al. showed 
that B-cells from tolerant recipients exhibit a down-regulation of B-cell differentiation 
genes7. Accordingly, we observed in tolerant patients lower levels of IgG1 in the sera 
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and lower secretion of the cytokines that contribute to the IgG class switching, IL-2 
and IL-4 compared to healthy volunteers. More specifically, IL-4 has been shown to 
induce the production of the IgG subclasses IgG1, IgG2 and IgG3, while IL-2 
promotes IgG1 and IgG3 release18,19. In addition, IL-2 produced by T-cells is 
required for ERK1/2-mediated differentiation of human naive B-cells into plasma 
cells23 and to enhance the effect of IL-10 for the induction of antibody production24. 
Furthermore, it has been shown that low levels of CD40 stimulation induced B-cell 
activation, whereas high levels of CD40 ligation inhibited Ig production11. Our results 
suggest that the imbalance in the BCR/CD40 signalling pathway and reduced IL-2 
and IL-4 secretion by T-cells may have prevented the class-switch and further 
secretion of IgG1 in these patients. In the context of transplantation, reduced levels 
of IgG1 decreased complement dependent cytotoxicity and Fc-receptors binding, 
therefore impairment in the humoral response of these patients could have promoted 
the tolerant state by reducing antibody-dependent cellular cytotoxicity25.  
Altogether our data suggest that the type of responses produced by B and T-cells in 
tolerant recipients may contribute to long-term stable graft function. Further studies 
are required to understand whether these responses were developed after 
transplant, as allograft-specific responses, or whether they are intrinsic or genetically 
determined in these patients. 
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Table 1 
Patient Data Healthy Control Tolerant 
Number of patients 
Age in years [mean (range)] 
11 
48.0 (23-72) 
16 
50.6 (22-77) 
Gender (Male/Female) (9/2) (13/3) 
Recipient age at Transpl. [mean (range)]  - 32.1 (11-56) 
Donor (Living/Deceased) - (9/7) 
Time post Transpl. in years [mean (range)]  - 18.4 (10-34) 
Years immunosuppression free [mean (range)] -  6.0 (1-23) 
 
HLA mismatches    
Number of patients with: 
-No mismatches - 6 
-HLA (A or B) mismatches - 2 
-HLA (A + B) mismatches - 1 
-HLA (A + DR) mismatches - 0 
-HLA (B + DR) mismatches - 0 
-HLA (A + B + DR) mismatches - 6 
-Missing data - 1 
 
Donor-specific antibodies (DSA)   
Number of patients with: 
-No DSA - 14 
-DSA Class I - 1 
-DSA Class II - 1 
-DSA Class I and II - 0 
 
Renal Function Parameters   
Creatinine (mmols/L) [mean] - 117.2 + 15.6  
eGFR (mL/min/1.73m2) [mean]  - 60.9 + 16.5 
 
Cell Count   
Lymphocytes count x 109 [mean+SD]   2.20 + 0.55 2.30 + 0.71 
B-cell count x109 [mean+SD] 0.43 + 0.24 0.46 + 0.21 
Memory B-cell count x109 [mean+SD] 0.12 + 0.10 0.11 + 0.07 
Naïve B-cell count x109 [mean+SD] 0.34 + 0.23 0.38 + 0.16 
Transitional B-cell count x109 [mean+SD] 0.03 + 0.03 0.05 + 0.02 
Table 1: Clinical data of tolerant kidney transplant recipients and healthy 
volunteers.  
DSA: donor-specific antibodies. eGFR: estimated glomerular filtration rate. 
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Fig. 1: Higher IL-10 production by B-cells from tolerant recipients was 
observed after CD40 ligation 
A) Comparison of the distribution of total, memory, naïve and transitional B-cells 
within PBMCs between healthy control (HC=11) and tolerant (Tol=16) patients. Total 
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B-cells were identified as CD20+CD19+, memory B-cells as CD27+, naïve B-cells as 
CD27-IgD+IgM+CD24+CD38+ and transitional B-cells as CD27-IgD+IgM+CD24hiCD38hi 
by surface staining. A Mann-Whitney test was used. B) Production of IL-10 and TNF-
 by intracellular staining and protein levels were measured after 3 days of activation 
with 0.5x105 non-transfected L-cells (Basal) or human-CD40L-transfected L-cells 
(CD40L) in 1.0x106 PBMCs from HC=8 and Tol=10 patients. Detection limit for IL-10 
and TNF- were 2 and 15.6pg/ml, respectively. C) The expression of CD25 and 
CD86 on CD20+ B-cells was measured after 3 days of activation with 0.5x105 non-
transfected L-cells (Basal) or human-CD40L-transfected L-cells (CD40L) in 1.0x106 
PBMCs from HC=11 and Tol=14 patients. D) Up-regulation of CD40L in CD4+T-cells 
from healthy HC=6 and Tol=7 patients were measured after 8hrs of activation with 
CD3/CD28 beads (1:2 ratio). Two-way RM ANOVA test with a Sidak’s multiple 
comparisons test was used. For all statistical tests **** P<0.0001, *** P<0.001, ** 
P<0.01 and * P<0.05 were considered significant. 
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Fig. 2: B-cells from tolerant recipients display a reduced ERK signalling after 
BCR activation.  
A) A phospho-flow B-cell panel was designed to identify p-ERK in B-cell subsets 
within PBMCs. B) A time course of p-ERK was measured in PBMCs after BCR-
activation [anti-IgM (20g/ml)/anti-IgG (20g/ml)] during 0, 10 and 30min at 37○C, 
using PMA (0.1M) for 10min as a positive control. C) Δp-ERK was defined as the 
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difference between the p-ERK MFI from a non-activated and a 10min BCR-activated 
sample. D) The BCR signalling was measured in 1x106 PBMCs from healthy control 
(HC=9) and tolerant (Tol=9) patients after BCR-activation or after E) PMA (0.1M) 
for 10min. F) IL-10 production after BCR/CD40 activation was measured by adding 
0.5x105 non-transfected or CD40L-transfected L-cells in 0.5x106 non-activated or 
BCR-activated B-cell subsets from healthy leukocytes retained in filtering cones after 
3 days of culture by intracellular staining. G) Levels of IL-10 were measured in the 
supernatants of 10x104 sorted transitional B-cells from 3 HC and 3 Tol recipients 
activated with 1x103 non-transfected or CD40L-transfected L-cells, with or without 
BCR activation for 3 days. H) IL-2 and IL-4 production from isolated CD4+T-cells of 
HC=6 and Tol=7 were measured after 48h of activation with CD3/CD28 beads (1:2 
ratio). Detection limit for IL-2 and IL-4 were 2.6 and 4.9pg/ml, respectively. I) Levels 
of IgG1 were measured in the sera from HC and Tol patients. Mann-Whitney test 
and two-way RM ANOVA test with a Sidak’s multiple comparisons test were used, 
**** P<0.0001, *** P<0.001, ** P<0.01 and * P<0.05 were considered significant. 
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Supplementary Methods 
 
Intracellular Staining 
Cells were activated with Phorbol 12-myristate 13-acetate (PMA) (50ng/mL, SIGMA), 
Ionomicyn (1g/mL, SIGMA), GolgiStop (1X, BD) and Brefeldin A (1X, BD) for 5hrs at 
37°C 5% CO2. Cells were stained with Live/Dead dye (Invitrogen), anti-CD20-
AlexaFluor780 and anti-CD3-PerCP-Cy5.5 (all eBioscience) for 30min at 4°C. 
Samples were then fixed and permeabilized with FoxP3 Fix and Perm Kit (BD) and 
stained with anti-IL10-PE (BD) and TNF- (eBioscience) for 30min at 4°C. Cells were 
acquired on LSRFortessa (BD).  
ELISA 
ELISA (eBioscience: IL-10) (R&D: TNF-) was performed according to manufacturer’s 
instructions. Briefly, 96-well plates (NuncTM, Thermo Scientific) were incubated 
overnight with capture antibody at 4°C. The next day, plates were blocked for 1hr with 
1%BSA, and standards and supernatant were added for 2hrs at room temperature. 
Detection antibody was added for 2hrs at room temperature and streptavidin-HRP was 
added for 20min at room temperature. Finally, plates were incubated with TMB 
(eBioscience) for 10min at room temperature and reaction was stopped using 0.5 M 
2N H2SO4. Optical density at 405nm was measured using Sunrise ELISA Reader 
(TECAN, UK). The concentration of each cytokine was calculated from standard 
curves using Magellan data analysis Software. For IL-10: the sensitivity of the kit was 
2 pg/mL and the standard curve range was from 2 to 300 pg/mL. For TNF-: the 
sensitivity of the kit was 15.6 pg/mL and the standard curve range was from 15.6 to 
1000 pg/mL. 
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B-cell subsets from peripheral blood cones  
RosetteSepTM Human B cell enrichment cocktail (STEM CELL, UK) was used to obtain 
purified CD20+B-cells from leukocytes retained filtering cones from healthy volunteers 
blood donations (NHSBT Tooting blood bank, UK). B-cell subsets were sorted with 
ARIA II (BD). Memory B-cells were CD20+CD27+ (purity >95%), naïve B-cells 
CD20+CD27-CD24+CD38+ (purity >95%) and transitional B-cells CD20+CD27-
CD24hiCD38hi (purity >95%). For IL-10 measurements in different B-cell subsets: 
0.5x106 B-cell subsets were cultured in complete media supplemented with IL-2 
(100ng/ml, R&D) with or without 1.0x104 plate bound CD40L-transfected and non-
transfected mouse L fibroblast cells (X-ray irradiated for 30min 9,045 cGy), and CpG 
– a TLR9 agonist - (1M; ODN 2006, InvivoGen) for 72hrs. After 3 days of activation, 
cells were stained with anti-CD20-AlexaFluor780 (eBioscience) and Live/Dead fixable 
yellow dead cell staining kit (Invitrogen) by surface staining and with IL-10-PE (BD) by 
intracellular staining for 30min at 4°C. For BCR signalling assays: 0.5x106 non-
activated or anti-IgM (20g/ml)/anti-IgG (20g/ml)-activated B-cell subsets were co-
cultured with 0.5x105 CD40L-transfected or non-transfected L-cells for 3 days. IL-10-
PE (BD) was detected by intracellular staining. Cells were acquired on an 
LSRFortessa (BD). Data was analysed using FlowJo (Tree Star, Inc. Ashland, OR 
97520. USA).  
IL-10 production by transitional B-cells from patients and healthy controls 
For IL-10 measurements in transitional B-cell subsets: 10x104 sorted transitional B-
cells from 3 healthy controls and 3 tolerant recipients were activated with 1x103 non-
transfected or CD40L-transfected L-cells, with or without BCR activation anti-IgM 
(20g/ml)/anti-IgG (20g/ml) for 3 days. IL-10 in the supernatants was measured using 
Cytometric Beads Array human Th1/Th2/Th17 kit (BD). For IL-10: the sensitivity of the 
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kit was 4.5 pg/mL and the standard curve range was from 4.5 to 5000 pg/mL. Beads 
were acquired on LSRFortessa (BD). 
Flow Cytometry settings were used to monitor staining panels in healthy 
volunteers and patients samples 
Flow cytometry panels in this study were monitored with CS&T (Cytometer Setup and 
Tracking, BD) beads, as a quality control for the Flow Cytometer; Application settings, 
as a quality control of the flow cytometry staining; and Inter and Intra-assay controls, 
as a quality control of the flow cytometry staining and the quality of the samples.    
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Supplementary Figures 
 
Supplementary Figure 1: B-cell subsets flow cytometry gating strategy. B-cells 
were identified as CD20+CD19+ B-cells. Within the B-cell population, memory B-cells 
were identified as CD27+ B-cells. IgM+IgD+ cells were gated from the CD27- B-cell 
population and from the IgM+IgD+ B-cells, naive B-cells were identified as 
CD24+CD38+ cells and transitional B-cells were identified as CD24hiCD38hi cells. 
Representative dot-plots of total, memory, IgD+IgM+, naïve and transitional B-cells 
were obtained from PBMCs from healthy controls (HC) and tolerant (Tol) patients by 
flow cytometry.  
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Supplementary Figure 2: IL-10 production by isolated B-cell subsets after 
CD40L and CpG activation. A) Sorted memory, naïve and transitional B-cells were 
obtained from healthy leukocytes retained in filtering cones. 0.5x106 sorted B-cell 
subsets were activated with 0.1x105 non-transfected L-cells or human-CD40L-
transfected L-cells B) and with or without CpG (1M) for 72hrs. ELISA and intracellular 
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staining were used to measure IL-10 and TNF-. Two-way RM ANOVA test with a 
Sidak’s multiple comparisons test was used. For all statistical tests **** P<0.0001, *** 
P<0.001 and ** P<0.01 were considered significant. 
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Supplementary Figure 3: IL-10 production by isolated B-cell subsets after 
CD40L, BCR and CD40/BCR activation. 
IL-10 production after CD40, BCR and CD40/BCR activation was measured by adding 
0.5x105 non-transfected or CD40L-transfected L-cells in 0.5x106 non-activated or 
BCR-activated sorted memory, naïve and transitional B-cells obtained from healthy 
leukocytes retained filtering cones. B-cell subsets were activated for 72hrs and IL-10 
was detected with intracellular staining. 
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Supplementary Figure 4: ERK phosphorylation after BCR and CD40L activation. 
A) Phosphorylation of ERK was assessed by phospho-flow using non-activated 
samples as negative controls and PMA-activated samples as positive controls. 
Phosphorylation ERK after CD40L, BCR, or BCR/CD40 activation was measured by 
adding 0.5x105 non-transfected or CD40L-transfected L-cells in 0.5x106 non-activated 
or BCR-activated B-cells from healthy volunteers after 3 days of culture by phospho-
flow. B) ERK phosphorylation between different activating conditions was compared. 
Ordinary one-way ANOVA with a Tukey’s multiple comparisons test was used, **** 
P<0.0001, *** P<0.001, ** P<0.01 and * P<0.05 were considered significant. 
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Supplementary Figure 5: Schema of B-cell from tolerant recipients. 
 B-cells from tolerant patients exhibit higher percentages of IL-10-producing B-cells 
after CD40 activation with limited evidence of concomitant pro-inflammatory cytokines 
in parallel and reduced BCR signalling all when compared to B-cells from healthy 
controls. Reduction in the BCR signalling favoured IL-10 production in the transitional 
B-cell population of tolerant recipients. In addition, reduced IL-2 and IL-4 production 
by T-cells, may contribute to the low IgG1 levels observed in the serum. Schema based 
on data from this manuscript and Nova-Lamperti et al., 201614. 
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Tolerant 
Cause of end-stage renal 
disease 
 
Tol 1 
Glomerular 
Disease 
-Mesangial GN and Malignant Hypertension 
Tol 2 
Genetic 
Disorder 
-Polycystic Kidney Disease 
Tol 3 
Other -Unknown, possibly B-cell lymphoproliferative 
disorder 
Tol 4 Other -Traumatic loss of Kidney after Road accident 
Tol 5 Other -Unknown 
Tol 6 
Diabetes -Diabetes type 2. Biopsy proven 
Nephropathy. Patient has Marfan Syndrome 
Tol 7 
Glomerular 
Disease 
-Membranoproliferative GN Type 1 
Tol 8 Pyelonephritis -Pyelonephritis/Reflux Nephropathy 
Tol 10 
Glomerular 
Disease 
-Membranous GN 
Tol 11 Pyelonephritis -Unknown, possibly chronic pyelonephritis 
Tol 12 
Genetic 
Disorder 
-Congenital Renal Dysplasia 
Tol 13 
Glomerular 
Disease 
-Membranoproliferative GN 
Tol 14 
Glomerular 
Disease 
-Mesangial GN and Malignant Hypertension 
Tol 15 Other -Drug Induced ESRF post-leukemia 
Tol 16 
Glomerular 
Disease 
-GN 
 
Supplementary Table 1: Causes of Kidney failure or end-stage renal disease 
(ESRD) in tolerant kidney transplant recipients.  
Tol: Tolerant recipient. GN: Glomerulonephritis. ESRF: End-stage Renal Failure. 
 
 
